- Much has changed in the treatment of chronic lymphocytic leukemia in recent years. International recommendations clearly indicate a move away from immunochemotherapy toward new therapies. Currently, two groups of therapeutics are widely used. These are BTK inhibitors and BCL2 inhibitor drugs. What is important is that the availability of these therapies in Poland is firstly, and secondly: expanding," says Prof. Krzysztof Giannopoulos, head of the Department of Experimental Hematology at the Medical University of Lublin. The needs of hematologists now include better access to modern BTK inhibitor therapies. Therapies that combine two oral drugs are also not insignificant for patient comfort and systemic benefits.
Hematologists agree that it can be said that currently in Poland, patients with chronic lymphocytic leukemia are treated according to world standards. However, new studies are emerging that confirm that the direction of change, associated with the move away from immunochemotherapy, is also correct in groups of patients with a favorable prognosis.
- One can basically identify two areas that could be improved in terms of reimbursement. This is first-line treatment, for patients who have a favorable genet...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
